Stelara

New Novartis data presented at AAD reveals Cosentyx® is superior to Stelara …
Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013; 149(10):1180-1185 ... [...]
1
Like
Save
Novartis' CLEAR study shows Cosentyx superior to Stelara in delivering long …
In addition, Cosentyx is the first IL-17A inhibitor with positive phase III results for the treatment of active psoriatic arthritis and active ankylosing spondylitis and is now approved in Europe, the US, Ecuador, Bangladesh and the Philippines for ... [...]
4
Like
Save
New Novartis Data Reveals Cosentyx® is Superior to Stelara® in Psoriasis Patients
This is an important milestone in the treatment of psoriasis, a skin disease with significant physical and emotional impact on a patient's life. I am encouraged by the data from the CLEAR study as it validates Cosentyx® as an effective treatment option ... [...]
5
Like
Save
Novartis' Cosentyx superior to Stelara in delivering long-lasting skin …
Cosentyx is the first fully human interleukin-17A inhibitor approved for adults to treat moderate-to-severe plaque psoriasis, and was recently approved for the treatment of psoriatic arthritis and ankylosing spondylitis in the EU and US. "Cosentyx ... [...]
2
Like
Save